Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
Nephrology Dialysis Transplantation · 30.06.2023 · 38 (7) · 1655-1665
DOI: 10.1093/ndt/gfac320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.01.2023. Verfasst von Beatriz Sánchez Álamo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences Lund, Division of Nephrology Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Granulomatosis with Polyangiitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: European Renal Association, Vasculitis Foundation, Region Skåne.
Abstract (Originalsprache)
Background
Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV included in seven RCTs conducted by the EUVAS as well as to identify potential prognostic factors.
Methods
Long-term follow-up data were collected from questionnaires sent to the principal investigators of the original RCTs (1995–2012): MEPEX, NORAM, CYCAZAREM, CYCLOPS, IMPROVE, RITUXVAS and MYCYC, comprising 848 patients, all newly diagnosed with AAV. Relative survival estimates are presented for the study cohorts. Demographic, clinical and laboratory characteristics at trial entry were studied as potential prognostic factors in multivariable models.
Results
A total of 478 (56%) patients had granulomatosis with polyangiitis (GPA) and 370 (44%) had microscopic polyangiitis (MPA) with a mean age at diagnosis of 58 ± 14 years. The median follow-up time was 8 years (interquartile range 2.9–13.6). During the observation period there were 305 deaths and the main causes were infections (26%), cardiovascular disease (14%) and malignancies (13%). When compared with a matched cohort (regarding country, age group and sex) from the background population there were 14.2% more deaths among our cohort of AAV patients at 5 years, 19.9% at 10 years, 28.8% at 15 years and 36.3% at 20 years. The excess mortality occurred in all age groups. The estimated median survival time (from diagnosis) was 17.8 years (95% confidence interval 15.7–20). Among variables measured at baseline, advanced age, male sex, low estimated glomerular filtration rate and low platelet count were identified as predictors of death in a multivariate Cox model.
Conclusions
Patients with AAV still have an increased risk of mortality compared with the general population despite newer therapeutic regimens. Treatment complications and organ damage are the main causes of limited survival and infections remain the leading cause of mortality among patients with AAV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences Lund, Division of Nephrology Lund University, Lund, Sweden.
- Division of Immunology and Allergy, Department of Medicine, University Hospital of Lausanne, Lausanne University, Switzerland.
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Rheumatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Nephrology, Royal Berkshire Hospital, Reading, Berkshire, UK.
- IZZ Immunologie-Zentrum Zürich, Zürich, Switzerland.
Förderung
- European Renal Association
- Vasculitis Foundation
- Region Skåne
- Njurfonden
Zitieren
APA
Sánchez Álamo, B., Moi, L., Bajema, I., Faurschou, M., Flossmann, O., Hauser, T., Hruskova, Z., Jayne, D., Luqmani, R., Mahr, A., Åkesson, A., Westman, K., & EUVAS (2023). Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 38(7), 1655-1665. https://doi.org/10.1093/ndt/gfac320
Vancouver
Sánchez Álamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T, et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation. 2023;38(7):1655-1665. doi:10.1093/ndt/gfac320
BibTeX
@article{Snchezlamo2023,
author = {Sánchez Álamo, Beatriz and Moi, Laura and Bajema, Ingeborg and Faurschou, Mikkel and Flossmann, Oliver and Hauser, Thomas and Hruskova, Zdenka and Jayne, David and Luqmani, Raashid and Mahr, Alfred and Åkesson, Anna and Westman, Kerstin and EUVAS, EUVAS},
title = {Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {7},
pages = {1655--1665},
doi = {10.1093/ndt/gfac320}
}
EUVIMED